Compare VCYT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCYT | LQDA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2013 | 2018 |
| Metric | VCYT | LQDA |
|---|---|---|
| Price | $34.88 | $41.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $46.00 | $38.60 |
| AVG Volume (30 Days) | 824.1K | ★ 2.3M |
| Earning Date | 02-25-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $495,141,000.00 | $69,216,000.00 |
| Revenue This Year | $16.72 | $993.31 |
| Revenue Next Year | $11.31 | $219.14 |
| P/E Ratio | $94.90 | ★ N/A |
| Revenue Growth | 16.41 | ★ 343.41 |
| 52 Week Low | $22.61 | $11.26 |
| 52 Week High | $50.71 | $46.67 |
| Indicator | VCYT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 27.09 | 55.61 |
| Support Level | $40.29 | $41.09 |
| Resistance Level | $38.98 | $46.67 |
| Average True Range (ATR) | 1.84 | 2.69 |
| MACD | -0.64 | 0.08 |
| Stochastic Oscillator | 0.14 | 50.82 |
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.